MPDL3280A for Non-Small Cell Lung Cancer

Roy S. Herbst, MD, PhD
Published Online:Jun 12, 2013


Roy S. Herbst, MD, PhD, a professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer (NSCLC).

Herbst presented data on MPDL3280A, which targets PD-L1. This agent produced a 21% response rate for patients with multiple solid tumors, including NSCLC, and had an acceptable toxicity profile.

These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC. Herbst says researchers and physicians now have new avenues for the treatment of this disease.

Clinical Pearls

  • MPDL3280A produced a 21% response rate for patients with multiple solid tumors, including NSCLC
  • MPDL3280A had an acceptable toxicity profile, with only a few patients having immune-related events
  • These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC


<<< View all coverage from the 2013 ASCO Meeting



Related Articles
$vAR$